The drugs we legalize kill orders of magnitude more than the ones we criminalize. Fentanyl was designed in a pharmaceutical lab. Psilocybin outperforms SSRIs in clinical trials. The War on Drugs has cost $1 trillion. The ledger was never meant to balance.
In 1959, a chemist named Paul Janssen synthesized fentanyl in a laboratory in Beerse, Belgium. The compound was 50 to 100 times more potent than morphine. Janssen Pharmaceutica patented it in 1964. Johnson & Johnson had already acquired the company in 1961. The molecule was designed for surgical anesthesia — a precise tool for a precise purpose.
Fentanyl worked. For decades, it remained what it was designed to be: a hospital drug, administered under medical supervision, reserved for severe pain. The crisis that now bears its name did not begin in Janssen’s laboratory. It began 36 years later, in a different company, with a different drug, and a very specific lie.
In 1996, Purdue Pharma launched OxyContin with a marketing campaign unprecedented in pharmaceutical history. Sales representatives were trained to tell physicians that “fewer than 1% of patients become addicted.” The source: a one-paragraph letter to the New England Journal of Medicine in 1980 — the Porter & Jick correspondence. It was not a study. It described hospitalized patients on short-term supervised opioid therapy. Purdue applied it to chronic outpatient pain.
First-year revenue: $48 million. By 2000: $1.1 billion. Between 1996 and 2001, Purdue hosted over 40 all-expenses-paid conferences at resort hotels. More than 5,000 physicians attended. The sales force grew 73%. Total OxyContin revenue over its lifetime exceeded $35 billion. The Sackler family extracted more than $10 billion from the company before it declared bankruptcy.
One of the most fundamental lessons of science is that a correlation or link between factors does not necessarily mean that one factor is the cause of another. This important principle, sadly, has rarely informed drug policy. — Carl Hart, Drug Use for Grown-Ups (2021)
In 2007, Purdue pled guilty to criminal misbranding. Fine: $634 million. In 2020, it pled guilty again — conspiracy to defraud the United States. In 2024, the Supreme Court overturned the Sackler bankruptcy shield. The final settlement: $7.4 billion. The Sacklers will pay $6.5 billion over 15 years.
Between 1999 and 2023, approximately 806,000 Americans died from opioid overdoses. The settlement amounts to roughly $9,180 per death. No member of the Sackler family has been criminally charged.
While Purdue Pharma was marketing OxyContin at resort conferences, the United States was spending $34.6 billion per year on the War on Drugs. The federal drug control budget grew from $81 million in 1969 to an estimated $41 billion by 2022 — a 1,090% increase adjusted for inflation. Total spending since President Nixon declared the War on Drugs in 1971: more than $1 trillion.
The results: 44 to 46 percent of all federal prisoners — roughly 89,000 out of 154,000 — are incarcerated for drug offenses. This is the single largest category in the federal prison system. Across all facilities (federal, state, local), approximately 361,000 people sit in cells for drug-related crimes. Over one million drug arrests were made annually before the pandemic.
Many of our most basic assumptions about this subject are wrong. Drugs are not what we think they are. Drug addiction is not what we have been told it is. The drug war is not what our politicians have sold it as for one hundred years and counting. — Johann Hari, Chasing the Scream (2015)
Portugal (2001–present). In 2001, Portugal decriminalized personal possession of all drugs. The penalty shifted from criminal prosecution to referral to Dissuasion Commissions — panels of psychologists, social workers, and legal advisors who connect users to treatment instead of prison.
Results after 20+ years: drug-related deaths dropped from 76 per year (2001) to 10 (2011) — an 87% reduction. HIV diagnoses among people who inject drugs plummeted from 1,287 in 2001 to 16 in 2019 — a 98.8% reduction. Drug use among young adults (15–34) dropped to consistently below the EU average. By 2019, Portugal’s drug death rate was 6 per million, compared to the EU average of 23.7.
The honest caveat: post-2009 austerity cuts reduced treatment funding. Drug deaths rose from the 2011 low but remain well below 2001 levels. High-risk opioid users numbered 33,290 in 2015 — above the EU average. Portugal proves that decriminalization works when paired with comprehensive health services. When funding is cut, outcomes deteriorate.
Oregon, USA (2021–2024). Oregon’s Measure 110, passed in November 2020 with 58.5% voter approval, made the state the first in the US to decriminalize personal drug possession. The penalty became a $100 fine. Cannabis tax revenue — $265 million — was allocated to treatment and harm reduction.
The experiment was confounded from the start. COVID-19 disrupted services. Illicitly manufactured fentanyl flooded Oregon’s supply simultaneously. Treatment funding disbursement was slow — bureaucratic delays meant services weren’t ready when decriminalization took effect. Open drug use in Portland became a political flashpoint.
The data tells a more complicated story than the headlines. A 2024 Brown University study found that after controlling for fentanyl spread as a confounder, Measure 110 was not associated with increased overdose deaths. Oregon’s overdose death increase was comparable to neighboring states that did not decriminalize. Violent crime did not increase. But public frustration with visible drug use was real, and in April 2024, the governor signed a recriminalization bill. Effective September 2024, drug possession is again a misdemeanor punishable by up to six months in jail.
Oregon proves that decriminalization without simultaneous treatment infrastructure is insufficient. It does not prove that decriminalization causes overdose deaths — the data, properly analyzed, does not support that claim.
Switzerland (2014–present). Since 2014, Switzerland has operated a limited medical use program allowing physicians to prescribe MDMA, LSD, and (since 2021) psilocybin for treatment-resistant conditions. In 2024, approximately 100 authorized physicians treated 723 patients: 348 with psilocybin, 245 with MDMA, 130 with LSD. Approximately 1,660 psychedelic-assisted treatments were administered.
The Netherlands (1976–present). For nearly 50 years, the Dutch “coffee shop” model has tolerated the sale of small amounts of cannabis. The results: cannabis use rates at or below comparable European countries. A gateway effect minimized — only 14% of Dutch cannabis users can access other drugs from their source, compared to 52% in Sweden. Low HIV among people who inject drugs. Lower youth cannabis use than many stricter countries.
British Columbia, Canada (2023–2026). In January 2023, BC decriminalized possession of small amounts (≤2.5g) of opioids, cocaine, methamphetamine, and MDMA. Opioid hospitalization rates dropped from 10 per 100,000 (Q1 2024) to 6 per 100,000 (Q3 2024). But 51% of users still hesitated to access services due to persistent stigma. Public spaces were re-criminalized in May 2024. The exemption expires January 2026 and will not be renewed.
In 2021, researchers at Imperial College London published a phase 2, double-blind, randomized controlled trial in the New England Journal of Medicine comparing psilocybin to escitalopram (a widely prescribed SSRI) for moderate-to-severe major depression. Fifty-nine patients were randomized: 30 to psilocybin (two 25mg doses with psychological support) and 29 to escitalopram (daily for 6 weeks with equivalent support).
The primary outcome (QIDS-SR-16 depression score at 6 weeks) did not reach statistical significance — though psilocybin showed a larger improvement (−8.0 vs −6.0). Remission at 6 weeks: 57% for psilocybin. Every secondary outcome measure — the Hamilton Depression Rating Scale, Montgomery-Åsberg scale, Beck Depression Inventory — significantly favored psilocybin. A 6-month follow-up published in Lancet eClinicalMedicine in 2024 showed sustained benefits.
The honest caveat: this was a small trial (n=59). It was not powered to detect differences on the primary outcome. The secondary outcomes were not pre-specified for multiple comparisons. The results are promising but not definitive. Psilocybin remains Schedule I under US federal law — classified as having “no accepted medical use.”
MDMA-assisted therapy for PTSD showed significant symptom reduction in clinical trials, but the FDA advisory committee voted 9–2 against effectiveness and 10–1 against approval in June 2024, citing functional unblinding, expectancy effects, and safety concerns. The FDA issued a Complete Response Letter in August 2024, requesting an additional Phase 3 trial.
Psychedelic drugs don’t change you — they don’t change your character — unless you want to be changed. They enable change; they can’t impose it. — Alexander Shulgin
Here is what the numbers say when placed side by side:
Tobacco, legal and unscheduled, kills 480,000 Americans per year. Alcohol, legal and unscheduled, kills 178,000. Together: 658,000 annual deaths from two substances available at every corner store.
Cannabis, federally illegal and Schedule I (“no accepted medical use, high potential for abuse”), has zero documented fatal overdoses from direct pharmacological toxicity. Psilocybin, also Schedule I, has no recorded fatal overdose and shows clinical evidence of antidepressant efficacy superior to SSRIs on multiple measures.
Fentanyl, originally synthesized in a Belgian pharmaceutical laboratory and approved by the FDA as a Schedule II drug, was responsible for 72,776 deaths in 2023. The pharmaceutical pipeline that created it — Janssen Pharmaceutica, Johnson & Johnson, and later Purdue Pharma’s OxyContin-driven overprescription epidemic — generated the demand that illicit manufacturers now fill.
The War on Drugs has cost more than $1 trillion since 1971. It has resulted in 361,000 people incarcerated for drug offenses and over one million arrests annually. In the same period, overdose deaths have risen from negligible numbers to 105,007 per year.
The Sackler family, whose company pled guilty twice to criminal charges related to the deadliest drug crisis in American history, paid a $7.4 billion settlement — approximately 20% of the wealth they extracted from Purdue Pharma. None of them have spent a day in prison.
The ledger was never meant to balance. It was designed to protect certain kinds of profit and punish certain kinds of people.
The core of addiction doesn’t lie in what you swallow or inject — it’s in the pain you feel in your head. Yet we have built a system that thinks we will stop addicts by increasing their pain. — Johann Hari, Chasing the Scream (2015)
Portugal reduced HIV infections among drug users by 98.8% by treating addiction as a health problem. Switzerland prescribes psilocybin to 348 patients legally. The Netherlands has operated cannabis coffee shops for 50 years without societal collapse. The evidence exists. The alternative is running. Some countries are already living in it.
The question is not whether a different approach is possible. The question is who benefits from the current one.
← Back to Issue 06